Esophageal Cancer,Gastrointestinal Cancer Patient-Reported Outcomes from Mobocertinib Phase 1/2 Study in EGFR+ Metastatic NSCLC: EXCLAIM Extension Cohort Results Feb 24, 2023
Breast Cancer,HER2+ Comparing Trastuzumab Deruxtecan vs. Trastuzumab Emtansine in HER2+ Metastatic Breast Cancer Phase 3 Trial Feb 24, 2023
Breast Cancer,HER2+ Adjuvant T-DM1 vs. Trastuzumab in Residual HER2+ Breast Cancer: KATHERINE Phase 3 Results Feb 24, 2023
CLL (Chronic Lymphocytic Leukemia),Leukemia,Lymphoma Comparing Relapsed or Refractory CLL with Zanubrutinib and Ibrutnib Phase 3 Trial Feb 16, 2023
FL (Follicular Lymphoma),Lymphoma Subcutaneous Epcoritamab Phase II Trial in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion Study Feb 16, 2023
DLBCL (Diffuse Large B Cell Lymphoma),Lymphoma Ibrutinib Plus R-CHOP for BCL2 and MYC Co-Expressing DLBCL: Phase 3 Results from the PHOENIX Trial Feb 16, 2023
Gastrointestinal Cancer,Liver Cancer Analyzing the Exposure-Response of Tremelimumab and Durvalumab in Patients with Unresectable HCC Feb 16, 2023
Lung Cancer,NSCLC (Non-Small Cell Lung Cancer),Popular KEYNOTE-407 Study: Pembrolizumab Plus Chemo in Squamous NSCLC Feb 16, 2023
